Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8

BACKGROUND: Paclitaxel (PTX) is a potent anti-cancer drug commonly used for the treatment of advanced breast cancer (BCA) and melanoma. Toll-like receptor 4 (TLR4) promotes the production of pro-inflammatory cytokines associated with cancer chemoresistance. This study aims to explore the effect of T...

Descripción completa

Detalles Bibliográficos
Autores principales: Sootichote, Rochanawan, Thuwajit, Peti, Singsuksawat, Ekapot, Warnnissorn, Malee, Yenchitsomanus, Pa-thai, Ithimakin, Suthinee, Chantharasamee, Jomjit, Thuwajit, Chanitra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830047/
https://www.ncbi.nlm.nih.gov/pubmed/29486738
http://dx.doi.org/10.1186/s12885-018-4155-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830047/
https://www.ncbi.nlm.nih.gov/pubmed/29486738
http://dx.doi.org/10.1186/s12885-018-4155-6

Ejemplares similares